FDA and EMA Release Joint Guiding Principles for Good AI Practice in Drug Development
On January 14, 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published a set of 10 guiding principles for the responsible, effective, and trustworthy use of artificial intelligence (AI) across the entire drug product life cycle — from early discovery through post-marketing pharmacovigilance. The announcement, distributed through official channels including the FDA China Office, marks the first formal collaborative framework between the two largest medicines regulators on AI good practice (GPAI). It reflects several months of intensive bilateral work and is intended to serve as a foundational reference for industry, academic researchers, international standards bodies, and other regulators worldwide. The 10 Guiding Principles – High-Level Summary While the full text is not reproduced in the announcement, the principles address the following core areas (based on the joint statement and typical content of such…


